Merck & Co., Inc. (NYSE:MRK) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Merck & Co., Inc.

Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 ...

The cancer biologics market presents significant opportunities driven by a rising global cancer incidence, increased R&D in personalized medicine, and advancements in biologic therapies like mRNA and ...

CNBC's Jim Cramer said Moderna's expanding pipeline in treatments for cancer and other diseases provides a compelling ...

Haircare experts are going for a silver metal. Emerging research says that it may be possible to reverse the effects of ...

Sen. Maggie Hassan is pressing pharmaceutical giant Merck over access and cost issues around one of its most popular and best ...

Roche's chief medical officer, Levi Garraway. Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new ...

AURORA targets a high-unmet-need population: metastatic non-squamous NSCLC with progression on pembrolizumab and platinum ...

Merck (NYSE: MRK) closed Tuesday's session down 0.87% at $128.26, breaking a six-session winning streak. The stock had gained 13.62% over the preceding six trading sessions, outperforming the S&P 500, ...

Pembrolizumab is used to treat various types of cancer, including melanoma, non-small cell lung cancer and head and neck squamous cell cancer.

Pfizer expands its oncology portfolio after EU approval for the Keytruda and Padcev regimen, strengthening its cancer ...

Replimune Group, Inc. nears a pivotal FDA AdCom for RP1 ahead of an Aug 2, 2026 decision. Click for this REPLY stock update ...